Do Different TSH Suppression Levels Effect Heart Rate Variability and QT Dispersions in Patients with Differentiated Thyroid Cancer?

被引:0
|
作者
Celik, Semih [1 ]
Uc, Ziynet Alphan [2 ]
Candan, Ozkan [3 ]
机构
[1] Usak Univ, Usak Training & Res Hosp, Fac Med, Dept Internal Med, Usak, Turkiye
[2] Usak Univ, Usak Training & Res Hosp, Fac Med, Dept Endocrinol & Metab, Fevzi Cakmak Mah Denizli St 4, TR-64000 Usak, Turkiye
[3] Usak Univ, Usak Training & Res Hosp, Fac Med, Dept Cardiol, Usak, Turkiye
关键词
Heart rate variability; QT dispersion; thyroid cancer; TSH suppressive therapy; RISK; MORTALITY; THERAPY;
D O I
10.1080/07435800.2024.2383669
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to investigate changes in heart rate variability (HRV) and QT dispersion (QTd) in patients with differentiated thyroid cancer at different TSH suppression levels. Methods: The study included 125 DTC patients, who had been on TSH suppression treatment (TSHST) for at least 1 year. The patients were categorized into three groups: patients with TSH < 0.1 mIU/L (n:30), those with TSH 0.1 to 0.5 mIU/L (n:56), and those with TSH 0.5 to 2 mIU/L (n:39). The first two groups were classified as suppression groups, and the last as replacement (control) group. All patients underwent 12-lead electrocardiogram (ECG) recording and 24-hour rhythm holter echocardiography analysis. Results: The HRV results derived from a 24-hour rhythm holter did not exhibit any significant difference (p < 0.05). In dispersion evaluations, the QTd was significantly longer in the suppression groups (groups 1 and 2), than in the replacement group (group 3) (p < 0.001 and p:0.002, respectively). The same was found for corrected QT dispersion (QTcd) (p < 0.001 and p: 0.008, respectively). In multivariate linear regression analysis, TSH was found to affect QTd (beta = -0.299; p = 0.002) and QTcd (beta = -0.300; p = 0.002) values independently. Conclusion: In this study, it was shown that in patients with DTC receiving TSHST, QT dispersion prolonged as the TSH suppression level increased. Especially in high-risk DTC patients, evaluation of QTd may be useful in terms of evaluating cardiovascular risk and regulating TSHST level.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 50 条
  • [21] Effect of palbociclib concentration on heart rate-corrected QT interval in patients with cancer
    Zheng, Jenny
    Amantea, Michael
    Wang, Diane
    CANCER RESEARCH, 2015, 75
  • [22] SERUM THYROGLOBULIN LEVELS IN PATIENTS WITH WELL-DIFFERENTIATED THYROID-CANCER DURING SUPPRESSION THERAPY - STUDY ON 429 PATIENTS
    GIRELLI, ME
    BUSNARDO, B
    AMERIO, R
    SCOTTON, G
    CASARA, D
    BETTERLE, C
    PICCOLO, M
    PELIZZO, MR
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1985, 10 (5-6): : 252 - 254
  • [23] Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
    Ha, Jeonghoon
    Kim, Min Hee
    Jo, Kwanhoon
    Lim, Yejee
    Bae, Ja Seong
    Lee, Sohee
    Kang, Moo Il
    Cha, Bong Yun
    Lim, Dong Jun
    MEDICINE, 2017, 96 (29)
  • [24] Age influences TSH serum levels after withdrawal of 1-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer
    Montesano, Teresa
    Durante, Cosimo
    Attard, Marco
    Crocetti, Umberto
    Meningolo, Domenico
    Bruno, Rocco
    Tumino, Salvatore
    Rubello, Domenico
    Al-Nahhas, Adil
    Colandlea, Marzia
    Maranghi, Marianna
    TravasCio, Laura
    Ronga, Giuseppe
    Torlontano, Massimo
    BIOMEDICINE & PHARMACOTHERAPY, 2007, 61 (08) : 468 - 471
  • [25] Factors influencing the therapeutic outcome of 131I therapy of differentiated thyroid cancer (DTC):: Do we really need stimulated TSH levels?
    Behr, TM
    Schipper, ML
    Gotthardt, M
    Gratz, S
    Höffken, H
    Béhé, MP
    Becker, W
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 80P - 81P
  • [26] L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer: Effect of a novel UGT1 marker, rs11563250A &gt; G
    Santoro, Ana Beatriz
    Struchiner, Claudio Jose
    Suarez-Kurtz, Guilherme
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (05) : 1402 - +
  • [27] The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
    Zygmunt, Arkadiusz
    Krawczyk-Rusiecka, Kinga
    Skowronska-Jozwiak, Elzbieta
    Wojciechowska-Durczynska, Katarzyna
    Glowacka, Ewa
    Adamczewski, Zbigniew
    Lewinski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [28] Variability of Serum Thyroglobulin Levels in Post-Thyroidectomy Patients with Well-Differentiated Thyroid Cancer: the ATA Guidelines
    Silva, Frieda
    Martin, Ralph J.
    Figueroa, Jannette
    Rincon, Fernando
    Roman, Diego
    PUERTO RICO HEALTH SCIENCES JOURNAL, 2016, 35 (03) : 142 - 146
  • [29] The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis
    Gubbi, Sriram
    Al-Jundi, Mohammad
    Foerster, Peter
    Cardenas, Stephanie
    Butera, Gisela
    Auh, Sungyoung
    Wright, Elizabeth Chalmers
    Klubo-Gwiezdzinska, Joanna
    THYROID, 2024, 34 (06) : 674 - 686
  • [30] The Levels of FT3/FT4 and Levothyroxine Dosage Required for TSH-Suppression in Differentiated Thyroid Carcinoma Patients Decrease over Time
    Verburg, F. A.
    Maeder, U.
    Luster, M.
    Reiners, C.
    Smit, J. W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S375 - S375